Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics Inc (OTLC) is a clinical-stage biopharmaceutical company advancing innovative therapies for cancer treatment through precision medicine and targeted drug development. This page consolidates official news releases and verified updates, providing stakeholders with a reliable resource for tracking the company’s progress in oncology research.
Investors and industry observers will find timely information on clinical trial milestones, regulatory developments, and strategic partnerships with pharmaceutical collaborators. The curated news feed also covers financial disclosures and operational updates critical for assessing OTLC’s position in the competitive oncology therapeutics market.
Content is organized to highlight key areas of interest including R&D advancements, technology innovations, and corporate governance updates. Regular visitors can stay informed about the company’s efforts to address unmet medical needs through its pipeline of novel cancer therapies.
Bookmark this page for direct access to Oncotelic Therapeutics’ latest announcements, or subscribe to Stock Titan’s alerts for real-time updates on OTLC’s developments in oncology research and biopharmaceutical collaborations.
Oncotelic Therapeutics (OTCQB:OTLC) announced that Product Manager Scott Myers will present at the 2nd Global Summit on Artificial Intelligence. The digital summit focuses on 'Pioneering the New Era: Advancing Global Development through Artificial Intelligence.' Myers will discuss the PubMed Corpus Builder, part of the Orion AI Suite developed by Sapu Bioscience
The PubMed Corpus Builder uses AI and LLMs to create comprehensive document corpora from the PubMed Central Database. It generates multiple search queries, downloads documents, and refines selection using vector search. The tool can identify documents with specific types of graphs and interpret them using multimodal technology. This system significantly accelerates the research process, allowing scientists to efficiently filter through hundreds of documents in minutes.
Oncotelic Therapeutics (OTCQB:OTLC) announced that its CEO, Dr. Vuong Trieu, will present at the 20th Annual Congress of International Drug Discovery Science & Technology in Budapest, Hungary, from June 17-19, 2024. Dr. Trieu will discuss OT-101, an antisense therapeutic targeting TGFB2, currently in phase 3 clinical trials for pancreatic cancer and glioblastoma. The presentation will also cover the potential of OT-101 in treating colorectal cancer (CRC), supported by clinical and bioinformatic analyses. Preliminary results indicate that OT-101 might prolong progression-free survival in CRC patients, particularly those with low TGFB2 and TGFM6 expression. Further analysis reveals a significant survival benefit in patients with low TGFB2/TGM6 expression. These findings could position OT-101 as a promising treatment for CRC, melanoma, and pancreatic cancer.
Oncotelic Therapeutics (OTCQB: OTLC) announced on May 30, 2024, that its CEO, Dr. Vuong Trieu, will attend the BIO International 2024 meeting in San Diego from June 3-6. The BIO International Convention is the largest biotech industry event, attracting over 18,500 global leaders.
Oncotelic Therapeutics announced that Chief Clinical Officer Dr. Anthony Maida will present at the ASCO 2024 meeting. Key topics include:
1. A meta-analysis (abstract e16318) comparing serious adverse events, overall survival, and progression-free survival in pancreatic adenocarcinoma patients treated with modified FOLFIRINOX versus the standard regimen.
2. A study (abstract e14564) on the prognostic impact of TGFB2 mRNA levels, interferon-gamma receptor activation of IRF5, and CD276/B7-H3 expression in low-grade gliomas.
The presentation aims to provide insights into treatment outcomes and prognostic factors in these cancers.
Oncotelic Therapeutics, Inc (OTCQB:OTLC) will be presenting at the Biopharma Nexus Conference in San Diego 2024. Dr. Andy Hu, Nanomedicine Manager, will discuss Nanomedicines: Past, Present, Future. Dr. Hu is an expert in nanomedicine and biotherapeutics, aiming to enhance human health through innovative technologies.
FAQ
What is the current stock price of Oncotelic Therapeutics (OTLC)?
What is the market cap of Oncotelic Therapeutics (OTLC)?
